|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF- and MEK-targeted therapies are effective in BRAF V600E/K metastatic melanoma and lung cancers; however, responses are short-lived due to emergence of resistance.
|
31744895 |
2020 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
|
30831205 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
|
30224342 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
|
31711466 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations are found in 1-5% of non-small cell lung cancers, particularly adenocarcinomas.
|
31440061 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
|
29516752 |
2018 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that AZ628 has greater potential than Dabrafenib, both as a single agent and combined with Trametinib, for the treatment of non-V600 BRAF mutant lung cancer.
|
29662630 |
2018 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for <i>EGFR</i>, anaplastic lymphoma kinase (<i>ALK</i>), <i>ROS1</i>, <i>BRAF V600</i> and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and <i>EGFR T790M</i> upon progression.
|
29507487 |
2018 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.
|
30038713 |
2018 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
|
29723688 |
2018 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CT features of BRAF mutated lung cancers were compared to stage matched lesions without BRAF mutation.
|
28012356 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.
|
28203297 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC).
|
28625649 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study provides a basis for the clinical exploration of non-V600 BRAF mutant lung cancers upon treatment with Trametinib and Dabrafenib.
|
28947956 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ATM loss also enhances the sensitivity of KRAS- or BRAF-mutant lung cancer cells to MEK inhibition.
|
27922010 |
2016 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAF fusions included 3% (14/531) of melanomas; 2% (15/701) of gliomas; 1.0% (3/294) of thyroid cancers; 0.3% (3/1,062) pancreatic carcinomas; 0.2% (8/4,013) nonsmall-cell lung cancers and 0.2% (4/2,154) of colorectal cancers, and were enriched in pilocytic (30%) vs. nonpilocytic gliomas (1%; p < 0.0001), Spitzoid (75%) vs. nonSpitzoid melanomas (1%; p = 0.0001), acinar (67%) vs. nonacinar pancreatic cancers (<1%; p < 0.0001) and papillary (3%) vs. nonpapillary thyroid cancers (0%; p < 0.03).
|
26314551 |
2016 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
One of our predicted biomarker pairs, a mutation in the BRAF gene and upregulated expression of the PIM1 gene, was experimentally validated to benefit from a therapy combining BRAF inhibitor and PIM1 inhibitor in lung cancer.
|
26916442 |
2016 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
|
27834212 |
2016 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our clinical data suggest that BRAF mutations define specific subsets of patients with NSCLC; while their oncogenic nature is yet to be established in lung cancer, especially for non-V600E mutations, the value of BRAF mutations to predict the efficacy of targeted agents remains unclear.
|
26711930 |
2016 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mutations (p.D594G [18%], p.V600E [14%], and p.G469A [9%]).
|
26386083 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Jointly, our results suggest a potential role of the novel BRAF fusion in lung cancer development and therapy.
|
25985019 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations.
|
25153497 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutants with impaired or unknown kinase activity as well as concomitant kinase-impaired BRAF mutations and RAS mutations were detected in lung cancers, colorectal cancers and melanomas.
|
26498038 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Recent evidence shows that BRAF-activated non-coding RNA (BANCR) acts as a critical role in the proliferation and metastasis in malignant melanoma and lung cancer; however, little is known about the significance of lncRNA BANCR in retinoblastoma.
|
25894373 |
2015 |